Geovax Labs Inc GOVX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if GOVX is a good fit for your portfolio.
News
-
GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine
-
GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress
-
GeoVax to Present at the 36th Annual Roth Conference
-
GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System
-
GeoVax Reports 2023 Year-End Financial Results and Provides Business Update
-
GeoVax to Report 2023 Financial Results and Provide Corporate Update on February 29, 2024
-
GeoVax to Present at the 2024 BIO CEO & Investor Conference
-
GeoVax Announces Multiple Patent Issuances and Allowances
Trading Information
- Previous Close Price
- $1.54
- Day Range
- $1.48–1.65
- 52-Week Range
- $1.45–11.54
- Bid/Ask
- $1.49 / $1.64
- Market Cap
- $3.55 Mil
- Volume/Avg
- 35,420 / 42,515
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax’s product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 17
- Website
- https://www.geovax.com
Valuation
|
Metric
|
GOVX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.53 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
GOVX
|
|---|---|
Quick Ratio | 1.83 |
Current Ratio | 2.24 |
Interest Coverage | — |
Quick Ratio
GOVX
Profitability
|
Metric
|
GOVX
|
|---|---|
Return on Assets (Normalized) | −117.99% |
Return on Equity (Normalized) | −152.69% |
Return on Invested Capital (Normalized) | −157.45% |
Return on Assets
GOVX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Hfbbhcxx | Tbw | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Czpyvtl | Hgrzrh | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Hxfdvnh | Ndwtngy | $99.5 Bil | |
MRNA
| Moderna Inc | Rnhbsqb | Prlst | $38.8 Bil | |
ARGX
| argenx SE ADR | Dwkcftjm | Jctj | $21.4 Bil | |
BNTX
| BioNTech SE ADR | Qhyqnvk | Jpd | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Qmffmxm | Fvdly | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Hwmjxskb | Ppythb | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Rkrrfjtyvp | Kxqpd | $12.5 Bil | |
INCY
| Incyte Corp | Lppglqdc | Zgcpqlb | $11.6 Bil |